Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9603 posts found.

GSK’s Relovair moves into phase III

March 19, 2010 Research and Development GlaxoSmithKline, Relovair, Seretide, Theravance, respiratory

GlaxoSmithKline has started phase III asthma trials of Relovair, the respiratory treatment it is developing with San Francisco biopharma firm …
News

Cephalon to develop new class of cancer drug

March 19, 2010 Research and Development CRT, Cancer, Cancer Research UK, Cephalon

Pennsylvania-based Cephalon has signed a deal with the discovery arm of charity Cancer Research UK to develop a new class …
News

Talking Point: Responding to trial emergencies

March 19, 2010 Research and Development Talking Point, Talking R&D, research and development

Patients taking part in a clinical trial will sometimes experience a medical emergency, at which point the potential need to …
Feature

Tekturna fails to show heart attack benefit

March 17, 2010 Research and Development Diovan, Novartis, Tekturna, hypertension

Novartis’ hypertension treatment Tekturna has failed to show it helps patients recover from a heart attack when added to standard …
News

Study boost for atrial fibrillation drugs

March 17, 2010 Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban

Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …
News

WuXi’s growth slows

March 17, 2010 Research and Development CRO, China, WuXi

WuXi Pharmatech, one of China’s leading contract research organisations, has been motoring ahead in recent quarters while its western counterparts …
News
William Burns

Bill Burns joins Shire board

March 17, 2010 Research and Development, Sales and Marketing Shire, appointment, research and development, sales and marketing

Former Roche pharma chief executive Bill Burns has joined the board at Shire as a non-executive director. Burns has also …
Appointment

Edinburgh BioQuarter appoints commercialisation director

March 16, 2010 Research and Development Edinburgh BioQuarter, appointment, research and development

Dr Michael Capaldi has joined Scottish life sciences research hub Edinburgh BioQuarter as director of commercialisation. He will lead a …
Appointment
GSKstephenne

GSK promotes Jean Stephenne to chairman, biologicals

March 15, 2010 Research and Development, Sales and Marketing GlaxoSmithKline, appointment, research and development, sales and marketing

GlaxoSmithKline has appointed Jean Stephenne chairman of GSK Biologicals, the company’s global vaccines division.He is currently president and general manager of …
Appointment

Contract research news in brief

March 15, 2010 Research and Development Bilcare, CRO, Kendle, Lonza, Medidata, Melbourn, Quintiles, RDNIB

Our round-up of developments in the contract research sector includes updates from Kendle, Bilcare, Quintiles, Melbourn Scientific, Lonza, and Medidata …
News

Pfizer suffers late-stage cancer drug failures

March 12, 2010 Research and Development Cancer, Pfizer, Sutent, figitumumab

Pfizer has suffered late-stage trial failures for Sutent and lung cancer candidate figitumumab. Kidney cancer drug Sutent (sunitinib) failed to …
News

GSK expands inflammatory alliance

March 12, 2010 Research and Development Cellzome, GlaxoSmithKline, rheumatoid arthritis

GlaxoSmithKline has formed a second strategic alliance with Cellzome to research new treatments for inflammatory diseases. GSK will buy into …
News

Novartis buys into Transgene’s lung cancer candidate

March 11, 2010 Research and Development Novartis, Transgene, immunotherapy, lung cancer

French biotech company Transgene has signed a deal with Novartis for the future development and marketing of its potential lung …
News

Investments boost Irish pharma sector

March 11, 2010 Research and Development, Sales and Marketing Ireland, PPD, Warner Chilcott

Contract research organisation PPD has officially opened its new research laboratory in Athlone, Ireland, and started recruiting for the first …
News

Five-year cardiovascular study planned for Onglyza

March 10, 2010 Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes

Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …
News
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026